切换至 "中华医学电子期刊资源库"

中华眼科医学杂志(电子版) ›› 2020, Vol. 10 ›› Issue (05) : 288 -293. doi: 10.3877/cma.j.issn.2095-2007.2020.05.006

论著

泪腺腺样囊性癌高级别转化的临床病理学研究
张红1, 马建民2, 张勇1, 白玉萍1, 刘红刚1,()   
  1. 1. 100730,首都医科大学附属北京同仁医院病理科 头颈部分子病理诊断北京市重点实验室
    2. 北京同仁眼科中心 北京市眼科研究所 北京市眼科学与视觉科学重点实验室
  • 收稿日期:2020-09-09 出版日期:2020-10-28
  • 通信作者: 刘红刚
  • 基金资助:
    北京市医院管理中心"登峰"计划专项基金项目(DFL20190201)

High-grade transformation in lacrimal adenoid cystic carcinoma: a clinico-pathological study

Hong Zhang1, Jianmin Ma2, Yong Zhang1, Yuping Bai1, Honggang Liu1,()   

  1. 1. Department of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology
    2. Beijing Tongren Eye Cener, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Ophthalmology & Visual Sciences Key Lab., Beijing 100730, China
  • Received:2020-09-09 Published:2020-10-28
  • Corresponding author: Honggang Liu
引用本文:

张红, 马建民, 张勇, 白玉萍, 刘红刚. 泪腺腺样囊性癌高级别转化的临床病理学研究[J/OL]. 中华眼科医学杂志(电子版), 2020, 10(05): 288-293.

Hong Zhang, Jianmin Ma, Yong Zhang, Yuping Bai, Honggang Liu. High-grade transformation in lacrimal adenoid cystic carcinoma: a clinico-pathological study[J/OL]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2020, 10(05): 288-293.

目的

探讨泪腺腺样囊性癌高级别转化(LACC-HGT)的临床病理学特征。

方法

回顾性分析首都医科大学附属北京同仁医院病理科2011年1月至2019年12月间确诊的8例LACC-HGT病例。其中,男性4例(4只眼),女性4例(4只眼);年龄19~65岁,中位年龄44.5岁。记录所有患者的性别、年龄、首发症状、肿瘤大小及骨质破坏情况;观察组织病理学特点;利用免疫组织化学EnVision法标记P63、腺泡来源标志物转录因子SRY相关蛋白10(SOX10)、细胞角蛋白7(CK7)、分化簇117(CD117)、Ki-67、原癌基因MYB、人表皮生长因子受体-2(Her-2)及雄激素受体(AR)等的表达情况。

结果

8例LACC-HGT患者中,临床表现为眼球突出者5例,占62.5%(5/8);眼睑肿胀者1例,占12.5%(1/8);眼球突出伴眼睑肿胀者2例,占25%(2/8)。肿瘤大小2~5 cm,平均(3.50±0.92)cm。骨质破坏者6例,占75%(6/8)。2例随访数据不全,其余6例随访期间均出现转移,转移部位包括腮腺、肺、脑、骨及区域淋巴结等,其中4例死亡。患者存活时间3~54个月,中位生存时间26个月。8例肿物均为实性,肿物最大直径2~5 cm,平均3.5 cm。肿物切面灰白、实性且质地中等,与周围组织边界不清。8例LACC-HGT病例中均可见经典ACC区域。其中,低级别的筛状型结构者2例,占25%(2/8);实性型结构者3例,占37.5%(3/8);筛状与实性混合型且实性成分>30%者3例,占37.5%(3/8)。高级别转化(HGT)区域占肿瘤镜下总面积的比例为60%~90%,肿瘤细胞排列呈实性未分化癌或低分化腺癌形态,片状;实性片巢常大于一个低倍镜视野。细胞异型性明显,胞核显著增大,核仁及核分裂象易见(平均38.75个/10高倍镜视野)。病理组织学显示神经浸润者8例,占100%(8/8);脉管侵犯者5例,占62.5%(5/8);间质促纤维结缔组织反应者7例,占87.5%(7/8);坏死者6例,占75%(6/8),其中4例伴钙化。免疫组织化学染色显示在经典腺样囊性癌(ACC)区域,P63在管周、筛周及筛孔周的肌上皮细胞核表达,在实性巢中可呈斑驳状表达;CK7和CD117在管腔面腺上皮以及筛状结构中向导管分化的细胞表达,而在实性巢中表达较弥漫;MYB蛋白在肌上皮和腺上皮中均呈胞核表达;在HGT区域,P63阳性肿瘤细胞明显减少,部分区域完全消失,而CK7和CD117在肿瘤中呈胞膜弥漫强阳性表达,提示腺泡来源的标志物SOX10呈胞核阳性表达,MYB蛋白亦呈核阳性表达。Ki-67增殖指数在HGT区域约为40%~70%(平均52.5%),在经典ACC区域约为10%~30%(平均15%)。Her-2和AR在ACC及HGT区域均呈阴性表达。

结论

LACC-HGT组织病理学特征显著,生物学行为差,病理医师应根据组织病理学及免疫组织化学特点做出正确诊断,以指导临床治疗及预后评估。

Objective

To investigate the clinico-pathological characteristics of lacrimal adenoid cystic carcinoma with high-grade transformation (LACC-HGT).

Methods

The clinical and pathological data of 8 cases of LACC-HGT were retrospectively analyzed. Among of them, there were 4 males (4 eyes) and 4 females (4 eyes); aged from 19 to 65 years old with a median age of 44.5 years old. Gender, age, first symptoms, tumor size and bone destruction of all patients were recorded, and histopathological characteristics were observed. Immunohistochemical study for P63, SOX10 (SRY-related HMG box 10 protein), cytokeratin 7 (CK7), cluster of differentiation 117 (CD117), Ki-67, MYB, human epidermal growth factor receptor 2 (Her-2) and androgen receptor (AR) was carried out.

Results

Among of these cases, 5 cases had exophthalmos, accounting for 62.5% (5/8); 1 case had swollen eyelids, accounting for 12.5% (1/8); 2 cases had exophthalmos with swollen eyelids, accounting for 25% (2/8). The tumor size was 2 to 5 cm with an average of (3.50±0.92) cm. 6 cases had bone destruction, accounting for 75% (6/8). Follow-up data of 2 cases were incomplete. 4 cases died of the remaining 6 cases with complete follow-up data all who had metastasis, and the metastatic sites included parotid gland, lung, brain, bone and regional lymph nodes. The survival time of the dead patients was 3 to 54 months, with a median survival time of 26 months. 8 cases of masses were all solid, with a maximum diameter of 2 to 5 cm and an average of 3.5 cm. The cut surface of the tumor was gray, solid and medium in texture, and the boundary with the surrounding tissue was not clear. The classic adenoid cystic carcinoma (ACC) area was shown in all 8 cases, of which showed low-grade cribriform structures (2 cases), accounting for 25% (2/8), solid structures (3 cases), accounting for 37.5% (3/8). 3 cases had cribriform and solid mixed structures and solid content>30%, accounting for 37.5% (3/8). The high-grade transformation (HGT) area accounted for 60% to 90% of the total tumor areas. LACC-HGT presented either as solid undifferentiated carcinoma or poorly differentiated adenocarcinoma. Histological examination showed obvious cell atypia, significantly enlarged nucleus, and prominent nucleoli and active mitosis (average 38.75/10 high power field). Nerve invasion (8 cases) and vascular invasion (5 cases) were observed, accounting for 100% (8/8) and 62.5% (5/8), respectively. Desmoplastic reaction (7 cases) and necrosis (6 cases) were found, accounting for 87.5% (7/8) and 75% (6/8), respectively. 4 cases with necrosis were accompanied by calcification. Immunohistochemical staining showed that in ACC region, P63 was expressed in the nucleus of myoepithelial cells in the peritubular and pericribriform areas, and shown in a mottled pattern in the solid nests. CK7 and CD117 were expressed in the luminal facial glands in tubular or cribriform areas, and more diffusely expressed in solid nests. MYB protein was expressed in nuclei of both myoepithelial and glandular epithelium. In HGT areas, P63-positive tumor cells were decreased, even disappeared completely in some areas, and CK7 and CD117 were diffusely and strongly positively expressed. The acinar-derived marker SOX10 was positively expressed in the nucleus, as well as MYB protein. The Ki-67 proliferation index was about 40% to 70% (average 52.5%) in the HGT region, and about 10% to 30% (average 15%) in the classic ACC region. Her-2 and AR were negatively expressed in ACC and HGT regions.

Conclusions

LACC-HGT was showd distinctive histopathological features and poor biological behaviors. Accurate diagnosis should be confirmed based on histopathological and immunohistochemical characteristics, which is significant to guide clinical treatment and prognostic evaluation.

图2 光学显微镜下泪腺ACC高级别转化免疫组织化学Envision二步法染色的图像(×200) 图2A示转化区域P63阳性肌上皮细胞明显减少,部分区完全消失,右上角插图示非转化区域肌上皮细胞分布在筛周及筛孔周;图2B示转化区域CK7弥漫强阳性表达于细胞膜;图2C示转化区域CD117弥漫强阳性膜表达;图2D示转化区域SOX10蛋白呈核阳性表达;图2E示转化区域MYB蛋白阳性表达于细胞核;图2F示转化区域Ki-67增值指数显著增高 ACC,腺样囊性癌;CK7,腺上皮标志物细胞角蛋白7;CD117,分化簇117;SOX10,腺泡来源标志物转录因子SRY相关蛋白10
[1]
Bradley PJ. Adenoid cystic carcinoma evaluation and management: progress with optimism[J]. Curr Opin Otolaryngol Head Neck Surg, 2017, 25(2): 147-153.
[2]
Von Holstein SL, Rasmussen PK, Heegaard S. Tumors of the lacrimal gland[J]. Semin Diagn Pathol, 2016, 33(3): 156-163.
[3]
Nagao T. "Dedifferentiation" and high-grade transformation in salivary gland carcinomas[J]. Head Neck Pathol, 2013, 7: S37-S47.
[4]
Zhou Q, Chang H, Han YD, et al. High-grade transformation in adenoid cystic carcinoma: a clinicopathologic study[J]. Zhonghua Bing Li Xue Za Zhi, 2013, 42(2):106-110.
[5]
EI-Naggar AK, Chan JK, Grandis JR, et al. WHO classification of head and neck tumors[M]. Lyon: IARC Press, 2017: 164-165.
[6]
Szanto PA, Luna MA, Tortoledo ME, et al. Histologic grading of adenoid cystic carcinoma of the salivary glands[J]. Cancer, 1984, 54: 1062-1069.
[7]
Andrés CP, Juan PR, Patrick JB, et al. Adenoid cystic carcinoma of the head and neck - An update[J]. Oral Oncol, 2015, 51(7): 652-661.
[8]
Sanders JC, Mendenhall WM, Weming JW. Adenoid cystic carcinoma of the lacrimal gland[J].Am J Otolaryngol, 2016, 37(2): 144-147.
[9]
Falcone MM, Tran KD, avakoli M, et al. Adenoid cystic carcinoma of the lacrimal gland in a 14-year-old male[J]. Orbit, 2017, 36(6): 448-451.
[10]
Friedrich RE, Bleckmann V. Adenoid cystic carcinoma of salivary and lacrimal gland origin: localization, classification, clinical pathological correlation, treatment results and long-term follow-up control in 84 patients[J]. Anticancer Res, 2003, 23(2A): 931-940.
[11]
Zhang M, Fathy C, Breazzano MP, et al. Intra-arterial chemotherapy for lacrimal gland adenoid cystic carcinoma[J]. International ophthalmology clinics, 2017, 51(3): 143-152.
[12]
Barnes EL, Eveson JW, Reichart P, et al, eds. Head and Neck Tumours[M]. Lyon: IARC Press, 2005:221-222.
[13]
Costa AF, Altemani A, Hermsen M. Current concepts on dedifferention/high-grade transformation in salivary gland tumors[J]. Patholog Res Int, 2011: 325965.
[14]
Han J, Kim YD, Woo KI, et al. Long-term outcomes of eye-sparing surgery for adenoid cystic carcinoma of lacrimal gland[J]. Ophthal Plast Reconstr Surg, 2018, 34(1): 74-78.
[15]
Argyris PP, Pambuccian SE, Cayci Z, et al. Lacrimal gland adenoid cystic carcinoma with high-grade transformation to myoepithelial carcinoma: report of a case and review of literature[J]. Head Neck Pathol, 2013, 7(1): 85-92.
[16]
Seethala RR, Hunt JL, Baloch ZW, et al. Adenoid cystic carcinoma with high-grade transformation: a report of 11 cases and a review of the literature[J]. Am J Surg Pathol, 2007, 31(11): 1683-1694.
[17]
Miyazaki M, Aoki M, Koga K, et al. Adenoid cystic carcinoma with high-grade transformation forming spindle cell component of the submandibular gland[J]. Auris Nasus Larynx, 2019, 46(6): 934-939.
[18]
North JP, McCalmont TH, Fehr A, et al. Detection of MYB alterations and other immunohistochemical markers in primary cutaneous adenoid cystic carcinoma[J]. Am J Surg Pathol, 2015, 39(10): 1347-1356.
[19]
Emanuel P, Wang B, Wu M, et al. p63 immunohistochemistry in the distinction of adenoid cystic carcinoma from basaloid squamous cell carcinoma[J]. Mod Pathol, 2005, 18(5): 645-650.
[20]
Sato K, Ueda Y, Sakural A, et al. Adenoid cystic carcinoma of the maxillary sinus with gradual histologic transformation to high-grade adenocarcinoma: a comparative report with dedifferentiated carcinoma[J]. Virchows Arch, 2006, 448(2): 204-208.
[21]
Von Holstein SL, Fehr A, Pers M, et al. Adenoid cystic carcinoma of the lacrimal gland: MYB gene activation, genomic imbalances, and clinical characteristics[J]. Ophthalmology, 2013, 120 (10): 2130-2138.
[22]
Malhotra KP, Agrawal V, Pandey R. High grade transformation in adenoid cystic carcinoma of the parotid: report of a case with cytologic, histologic and immunohistochemical study[J]. Head Neck Pathol, 2009, 3(4): 310-314.
[23]
Xie J, Lin LS, Huang XY, et al. The NOTCH1-HEY1 pathway regulates self-renewal and epithelial-mesenchymal transition of salivary adenoid cystic carcinoma cells[J]. Int J Biol Sci, 2020, 16(4): 598-610.
[24]
Seethala RR, Cieply K, Barnes EL, et al. Progressive genetic alterations of adenoid cystic carcinoma with high-grade transformation[J]. Arch Pathol Lab Med, 2011, 135(1): 123-130.
[25]
Seethala RR.Histologic grading and prognostic biomarkers in salivary gland carcinomas[J].Adv Anat Pathol, 2011, 18(1): 29-45.
[26]
Pusztaszeri MP, Sadow PM, Ushiku A, et al. MYB immuno-staining is a useful ancillary test for distinguishing adenoid cystic carcinoma from pleomorphic adenoma in fine-needle aspiration biopsy specimens[J]. Cancer Cytopathol, 2014, 122(4): 257-265.
[27]
Chen TY, Keeney MG, Chintakuntlawar AV, et al. Adenoid cystic carcinoma of the lacrimal gland is frequently characterized by MYB rearrangement[J]. Eye (Lond), 2017, 31(5): 720-725.
[28]
刘尧,刘月平. WHO(2017)涎腺肿瘤分类解读[J]. 临床与实验病理学杂志201834(1): 1-3.
[29]
Serocki M, Bartoszewska S, Janaszak-Jasiecka A, et al. miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target[J]. Angiogenesis, 2018, 21(2): 183-202.
[30]
Hao J, Jin X, Shi Y, et al. miR-93-5p enhance lacrimal gland adenoid cystic carcinoma cell tumorigenesis by targeting BRMS1L[J]. Cancer Cell Int, 2018, 18(1): 72-84.
[31]
Zhang MX, Zhang J, Zhang H, et al. miR-24-3p suppresses malignant behavior of lacrimal adenoid cystic carcinoma by targeting PRKCH to Regulate p53/p21 Pathway[J]. PLoS One, 2016, 11(6): e0158433.
[1] 李雪, 韩萌萌, 冯雪园, 马宁. 人表皮生长因子受体2低表达乳腺癌的研究进展及挑战[J/OL]. 中华普通外科学文献(电子版), 2024, 18(04): 308-312.
[2] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[3] 黄福, 王黔, 金相任, 唐云川. VEGFR2、miR-27a-5p在胃癌组织中的表达与临床病理参数及预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 558-561.
[4] 孙建娜, 孔令军, 任崇禧, 穆坤, 王晓蕊. 266例首诊Ⅳ期乳腺癌手术患者预后分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 502-505.
[5] 蔡大明, 陆晓峰, 王行舟, 王萌, 刘颂, 夏雪峰, 沈晓菲, 杜峻峰, 管文贤. 三级淋巴结构在胃神经内分泌瘤中的预后价值及预后预测模型构建[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 401-405.
[6] 乌吉斯古楞, 哈斯高娃. mir-98-5p、ALKBH1在肝门部胆管癌组织中表达及与临床病理特征的关系[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(02): 184-187.
[7] 刘政宏, 王凤力, 吉亚君, 高佳. 胃癌中ELK3蛋白的表达与临床病理特征和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(02): 155-159.
[8] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[9] 王凯飞, 牟怡平, 李晓辉, 王瑞涛, 侯惠莲, 张月浪. 原发性肝平滑肌肉瘤临床病理特征及疗效分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 357-362.
[10] 程璞, 郑朝旭. 伴有错配修复缺陷的病理Ⅱ期结直肠癌临床病理特征分析及生存分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(03): 236-241.
[11] 孙鼎, 王滨, 陈香美, 陈意志. 热应激肾病的研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(03): 170-176.
[12] 王琳娜, 郭存霞, 乔东鸽, 赵旭, 阎磊, 邵凤民, 陈香美. 无高血压和糖尿病的特发性膜性肾病患者肾内动脉病变特点及其预后影响分析[J/OL]. 中华肾病研究电子杂志, 2024, 13(01): 39-45.
[13] 丁富贵, 吴泽涛, 董卫国. 家族性腺瘤性息肉病临床特征及生物信息学分析[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 512-518.
[14] 陈雪芬, 韦虹羽, 孙起翔, 赵华, 闫萍, 龚臣. 肺肝样腺癌诊治研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(01): 83-86.
[15] 董宁宁, 孟凡冬, 岳冰, 侯俊珍. 消化道幽门腺腺瘤的临床、内镜及病理特征分析[J/OL]. 中华胃肠内镜电子杂志, 2024, 11(03): 159-165.
阅读次数
全文


摘要